House Amendment 719 to House Bill 3
116th Congress(2019-2020)
An amendment numbered 9 printed in Part B of House Report 116-334 to require drug companies to disclose truthful and non-misleading pricing information about prescription drugs and biological products when they advertise these products directly to consumers.
Agreed To
Agreed to in House on Dec 12, 2019
Origin Chamber
House
Type
Amendment
Amendment
A proposed change to a pending text (e.g., a bill, resolution, another amendment, or a treaty [or an associated resolution of ratification]).
Amendment Number
719
Congress
116
Sort by most recent
12/12/2019
House amendment agreed to: On agreeing to the Finkenauer amendment (A009) Agreed to by voice vote.
12/12/2019
On agreeing to the Finkenauer amendment (A009) Agreed to by voice vote.
12/12/2019
Amendment (A009) offered by Ms. Finkenauer. (consideration: CR H10214-10215; text: CR H10214)
12/12/2019
House amendment offered
Dec 12, 2019
Passed House
107
Sponsorship
Public Record
Record Updated
Feb 8, 2022 11:01:28 PM